Skip to NavigationSkip to content

Business Services

J&J and Colgate pay $4.8 million each to woman in California

A California court has said Johnson & Johnson and Colgate-Palmolive must pay a total of nearly $10 million to a woman who developed cancer.

Colgate and J&J must pay Patricia Schmitz $4.8 million in damages each. The ruling comes after Schmitz developed mesothelioma after using J&J’s Baby Powder and Colgate’s Cashmere Bouquet. Schmitz was not awarded punitive damages.

AstraZeneca spends more than twice as much as expected on new HQ

Image Credit: AstraZeneca

AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the sum of £330 million that the firm budgeted for in 2013.

At a cost of £750 million so far, AstraZeneca’s new donut-shaped HQ is set to become one of the most expensive corporate buildings in the UK.  

According to AstraZeneca, the construction costs associated with the building of the 580,000 metres square headquarters on a biomedical campus south of Cambridge have soared due to “increased investment in new technologies and equipment.”

Novartis Pharma head to become new Sanofi CEO

Published on: 10/06/19

French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with Paul Hudson (pictured), CEO at Novartis Pharmaceuticals.

The decision was made on 6 June, when Sanofi’s Board of Directors voted unanimously to approve Brandicourt’s replacement. Hudson will take up the mantle on 1 September this year.

Vectura CEO to step down at end of June

Vectura is on course for a new leader to take up the company’s reins after it was revealed that CEO James Ward-Lilley is to step down from his role on 30 June.

During his time at the head of the company, Ward-Lilley served Vectura at a “critical time”, the company said, and this included presiding over its merger with Skyepharma. Prior to this, he spent 28 years in roles of increasing seniority at AstraZeneca.

Implementing “the safest medicines system in the world”

Published on 10/06/19 at 10:35am
Image courtesy of PCI Pharma Services

With debates heating up over cooperation between European across the continent, Matt Fellows investigates the current state of packaging countermeasures in the region after delegated regulation to the Falsified Medicines Directive came into force earlier this year.

Long-term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer

Published on: 07/06/19

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer.

In her new role Mercier will join Gilead’s senior leadership team when she takes over the California firm’s commercial operations on July 1.

Mercier, who served with BMS for more than ten years, brings a wealth of experience to the role. The experienced executive holds a degree in Biology from the University of Montreal and an MBA from Concordia University.

Novartis Pharma head to become new Sanofi CEO

Image Credit: By BHCSocialMedia - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=38594945

French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with Paul Hudson (pictured), CEO at Novartis Pharmaceuticals.

The decision was made on 6 June, when Sanofi’s Board of Directors voted unanimously to approve Brandicourt’s replacement. Hudson will take up the mantle on 1 September this year.

Marie-France Tschudin, head of Novartis subsidiary AAA, takes over from Paul Hudson as Novartis Pharma CEO

Published on: 07/06/19

Novartis has said Marie-France Tschudin will take over from Paul Hudson as the head of Novartis Pharmaceuticals.

The announcement comes after French firm Sanofi said that Paul Hudson, the current chief executive of Novartis Pharmaceuticals, will succeed Olivier Brandicourt as the company’s new CEO.

Top Ten most popular articles on Pharmafile.com this week!

It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. The revelation came as parents of children with cystic fibrosis clubbed together to form an Orkambi buyers club to import cheap generic versions of the drug into the UK.

Mallinckrodt illegally inflated price of drug from $50 to $32,000, DoJ lawsuit says

The Department of Justice (DoJ) has filed new charges against Mallinckrodt alleging the Irish-listed firm illegally hiked the price of a vial of the anti-inflammatory drug Acthar from $50 to $32,000.   

Mallinckrodt paid illegal kickbacks to encourage Medicare patients to buy their drugs, the lawsuit says.

The government alleges that Mallinckrodt used a foundation as a conduit to pay illegal kickbacks in the form of co-pay subsidies so that it could market the drug as ‘free’.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches